To confirm our findings, we analysed RNA-sequencing data from the cancer genome atlas (TCGA) and found BDH2 transcription downregulated in several kinds of cancer, including cervical and endocervical cancers (CESC), cholangiocarcinoma (CHOL), prostate adenocarcinoma (PRAD) and lung squamous cell carcinoma (LUSC) (Supplementary Fig. 1), suggesting that inactivation of BDH2 may be a common event in human cancers. This evidence concerns the gene BDH2 and cancer.